trending Market Intelligence /marketintelligence/en/news-insights/trending/jrOXlJ6G9ocEIetgLvngZA2 content esgSubNav
Log in to other products

 /


Looking for more?

Contact Us
In This List

Jyothy Laboratories profit misses consensus by 30.6% in fiscal Q3

Blog

COVID-19 Impact & Recovery: Healthcare Outlook for H2 2021

Blog

COVID-19 Impact & Recovery: LCD Outlook for H2 2021

Blog

COVID-19 Impact & Recovery: Technology Outlook for H2 2021

Blog

COVID-19 Impact & Recovery: Financial Industry Outlook for H2 2021


Jyothy Laboratories profit misses consensus by 30.6% in fiscal Q3

Jyothy Laboratories Ltd said its normalized net income for the fiscal third quarter ended Dec. 31, 2015, amounted to 1.54 Indian rupees per share, compared with the S&P Capital IQ consensus estimate of 2.21 rupees per share.

EPS climbed 68.2% year over year from 91 paise.

Normalized net income, which excludes unusual gains or losses on a pre- and after-tax basis, was 282.6 million rupees, a gain of 70.7% from 165.5 million rupees in the prior-year period.

The normalized profit margin climbed to 7.3% from 4.6% in the year-earlier period.

Total revenue rose 8.0% year over year to 3.85 billion rupees from 3.56 billion rupees, and total operating expenses rose on an annual basis to 3.41 billion rupees from 3.28 billion rupees.

Reported net income increased 47.4% from the prior-year period to 389.9 million rupees, or 2.12 rupees per share, from 264.6 million rupees, or 1.46 rupees per share.

As of Jan. 28, US$1 was equivalent to 68.14 Indian rupees.